January |
| ||||||
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Boehringer Ingelheim and 3T Biosciences to develop cancer immunotherapies | 3T Biosciences Inc. | Boehringer Ingelheim International GmbH | $270.50 | 1/4/2024 |
| 4DMT and Arbor Biotechnologies to co-develop and co-commercialize AAV-delivered CRISPR/Cas-based therapeutics for central nervous system diseases | 4D Molecular Therapeutics Inc. | Arbor Biotechnologies Inc. | Payment unspecified | 1/3/2024 |
| Allogene and Foresight to develop in-vitro diagnostic for use in alpha3 trial of ALLO-501A against large B-cell lymphoma | Allogene Therapeutics Inc. | Foresight Diagnostics Inc. | Payment unspecified | 1/4/2024 |
| Allorion and Avenzo Therapeutics to develop and commercialize ARTS-021 (AVZO-021) for HR-positive/HER2-negative metastatic breast cancer and other advanced solid tumors worldwide excluding greater China | Allorion Therapeutics Inc. | Avenzo Therapeutics Inc. | $1,040.00 | 1/4/2024 |
| AstraZeneca to obtain an option to develop and commercialize Allorion's EGFR L858R against NSCLC worldwide | Allorion Therapeutics Inc. | Astrazeneca plc | $540.00 | 1/2/2024 |
| Angle to provide CTC cell analysis for Eisai with portrait HER2 assay to assess phase II study of BB-1701 against breast cancer | Angle plc | Eisai Inc. | $0.25 | 1/2/2024 |
| Maruho to develop and commercialize Aobiome's B-244 for atopic dermatitis and all other indications in Japan | Aobiome Therapeutics Inc. | Maruho Co. Ltd. | Payment unspecified | 1/5/2024 |
| Passport Technologies and Arcturus Therapeutics to evaluate mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics | Arcturus Therapeutics Inc. | Passport Technologies Inc. | Payment unspecified | 1/5/2024 |
| Pharmalogic to manufacture and supply Artbio's AB-001 against prostate cancer | Artbio Inc. | Pharmalogic Holdings Corp. | Payment unspecified | 1/12/2024 |
| Specialised Therapeutics to commercialize Ascendis Pharma's Skytrofa, Yorvipath and TransCon CNP in Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and Vietnam | Ascendis Pharma A/S | Specialised Therapeutics Asia Pte. Ltd. | Payment unspecified | 1/7/2024 |
| Servier and Base4 Biotechnology expanded partnership developing RNA-targeted small-molecule therapeutics to include neuroscience drugs | Base4 Biotechnology Inc. | Servier SAS | Payment unspecified | 1/8/2024 |
| Radiance to develop, manufacture and commercialize Biocytogen's YH-012 against human indications worldwide, with an option | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. | Radiance Biopharma Inc. | Payment unspecified | 1/8/2024 |
| Radiance to receive an option to license Biocytogen's fully human anti-HER2/TROP2 bispecific antibody-drug conjugate for therapeutic product development, manufacturing and commercialization for all human indications worldwide | Biocytogen Pharmaceuticals Co. Ltd. | Radiance Biopharma Inc. | Payment unspecified | 1/8/2024 |
| Boryung to sell Baxter's Suprane for use as an inhalation anesthesia, and Lyte 148 for use as a blood substitute Plasma in South Korea | Boryung Pharmaceutical Co. Ltd. | Baxter Healthcare Corp. | Payment unspecified | 1/10/2024 |
| Galapagos to use Bridgene's Imtac platform to discover, develop and commercialize small molecule drug candidates against oncology targets | Bridgene Biosciences Inc. | Galapagos NV | $727.00 | 1/3/2024 |
| Cipla, Kemwell Biopharma and Manipal Education & Medical Group to establish a joint venture in the U.S. to develop and commercialize cell therapy products in the U.S., Japan and the EU | Cipla Ltd. | Kemwell Biopharma Pvt. Ltd.; Manipal Education & Medical Group | Payment unspecified | 1/8/2024 |
| CKD Bio to supply CKDB-501 to Healis for development against MDD and PTSD | CKD Bio Corp. | Healis Therapeutics LLC | Payment unspecified | 1/2/2024 |
| Inovio and Coherus to evaluate combination of INO-3112 and Loqtorzi against HPV16/18 positive oropharyngeal squamous cell carcinoma | Coherus Biosciences Inc. | Inovio Pharmaceuticals Inc. | Payment unspecified | 1/4/2024 |
| Connect to evaluate a phase II trial of Rigel's Rezlidhia in combination with temozolomide against high-grade glioma | Connect Consortium | Rigel Pharmaceuticals Inc. | $3.00 | 1/4/2024 |
| Cordavis to supply Abbvie's co branded Humira | Cordavis Ltd. | Abbvie Inc. | Payment unspecified | 1/3/2024 |
| Cordenpharma to manufacture Cereno Scientific's CS1 for pulmonary arterial hypertension | Cordenpharma International GmbH | Cereno Scientific AB | Payment unspecified | 1/11/2024 |
| Crosslink Life to distribute Heron' Zynrelef for orthopedic indications in the U.S. | Crosslink Bioscience | Heron Therapeutics Inc. | Payment unspecified | 1/7/2024 |
| CRT Pioneer Fund entered a development and commercialization license agreement for SRA-737 with an undisclosed private biopharma company based in the U.S | CRT Pioneer Fund | Undisclosed private biopharma company based in the U.S | $290.50 | 1/2/2024 |
| Debiopharm and Repare Therapeutics to evaluate Debio-0123 in combination with lunresertib against cancer | Debiopharm International SA | Repare Therapeutics Inc. | Payment unspecified | 1/4/2024 |
| Debiopharm and ThinkingNodeLife.ai to advance the development of a cancer drug | Debiopharm International SA | Thinkingnode Lifescience Inc. | Payment unspecified | 1/10/2024 |
| Emergex and Deka to evaluate the compatibility of DengueTcP with Intradermal Therapeutic Applicator against Dengue virus infection and other viral diseases | Deka Biosciences Inc. | Emergex Vaccines Ltd. | Payment unspecified | 1/16/2024 |
| Dong-A ST enters a MOU with Eleven Therapeutics to develop RNA-based gene therapy | Dong-A ST Co. Ltd | Eleven Therapeutics Ltd. | Payment unspecified | 1/11/2024 |
| Elektrofi and Janssen Biotech to develop home self-administered subcutaneous versions of oncology target and up to four additional targets | Elektrofi Inc. | Janssen Biotech Inc. | $638.00 | 1/2/2024 |
| Boehringer exercised its option to license the cancer antigens, discovered and validated through the Enara Bio’s EDAPT platform to develop off-the-shelf vaccines for non-small-cell lung cancer | Enara Bio Ltd. | Boehringer Ingelheim GmbH | Payment unspecified | 1/4/2024 |
| Willow Biosciences and Enterin to develop sustainable manufacturing routes to key intermediates and APIs | Enterin Inc. | Willow Biosciences Inc. | Payment unspecified | 1/16/2024 |
| Er-Kim to distribute Ascendis' Skytrofa, Yorvipath, TransCon CNP for growth hormone deficiency, hypoparathyroidism, and achondroplasia in Central & Eastern Europe and Turkey | Erkim Ilac A.S. | Ascendis Pharma A/S | Payment unspecified | 1/8/2024 |
| Evotec and Owkin to discover and develop new therapeutics in oncology, immunology and inflammation via artificial intelligence | Evotec SE | Owkin Inc. | Payment unspecified | 1/4/2024 |
| Orion and Glykos to develop antibody-drug conjugates against solid tumors | Glykos Finland Oy | Orion Corp. | Payment unspecified | 1/8/2024 |
| AFT and Hyloris to develop and commercialize HY-090 against burning mouth syndrome | Hyloris Pharmaceuticals SA | AFT Pharmaceuticals Ltd. | Payment unspecified | 1/8/2024 |
| NMS to use Iktos's expertise in drug design services to identify promising candidate molecule | Iktos | Nerviano Medical Sciences Srl | Payment unspecified | 1/8/2024 |
| Ildong Pharmaceutical to distribute Hanlim Pharm's Nazorin, Numaren, and Eyefeel to treat ophthalmic disease | Ildong Pharmaceutical Co. Ltd. | Hanlim Pharmaceutical Co. Ltd. | Payment unspecified | 1/10/2024 |
| Stemline Therapeutics to develop and commercialize a small molecule KAT6A inhibitor designed using Insilico's artificial intelligence platform | Insilico Medicine Inc. | Stemline Therapeutics Inc. | $512.00 | 1/4/2024 |
| Stemline to develop and commercialize Insilico's small molecule KAT6A inhibitor for hormone sensitive cancers and other oncology indications | Insilico Medicine Inc. | Stemline Therapeutics Inc. | $512.00 | 1/4/2024 |
| Merck to develop and commercialize Inspirna's Ompenaclid against RAS-mutated advanced or metastatic colorectal cancer worldwide, outside the U.S. | Inspirna Inc. | Merck KGaA | $45.00 | 1/4/2024 |
| Seismic Therapeutic to research, develop and commercialize Integral Molecular's antibodies | Integral Molecular Inc. | Seismic Therapeutic Inc. | Payment unspecified | 1/4/2024 |
| Inimmune and Intrommune Therapeutics to advance mucosal allergy immunotherapy for the treatment of peanut allergy | Intrommune Therapeutics | Inimmune Corp. | Payment unspecified | 1/8/2024 |
| Isomorphic Labs and Novartis to discover small molecule therapeutics against three undisclosed targets | Isomorphic Labs Ltd. | Novaris AG | $1,237.50 | 1/7/2024 |
| Isomorphic Labs and Eli Lilly to discover small molecule therapeutics against multiple targets | Isomorphic Labs Ltd. | Eli Lilly and Co. | $1,745.00 | 1/7/2024 |
| Boehringer Ingelheim to develop and commercialize Kyowa Kirin’s therapy against fibro-inflammatory diseases, worldwide | Kyowa Kirin Co. Ltd. | Boehringer Ingelheim International GmbH | $441.24 | 1/5/2024 |
| LG Chem to commercialize Kyowa Kirin's Nephoxil against hyperphosphatemia in Korea | Kyowa Kirin Co. Ltd. | LG Chem Ltd. | Payment unspecified | 1/11/2024 |
| Rhythm to develop and commercialize LG Chem's LB-54640 for obesity worldwide | LG Chem Life Sciences Innovation Center Inc. | Rhythm Pharmaceuticals Inc. | $305.00 | 1/4/2024 |
| GC Cell to enhance precision and clinical intelligence of AB-201's efficacy evaluation via Lunit’s advanced AI technology | Lunit Inc. | GC Cell Corp. | Payment unspecified | 1/8/2024 |
| Lion TCR to utilize Maxcyte's flow electroporation technology and Expert platform to develop TCR-T cell therapies for solid tumors and viral-related diseases worldwide | Maxcyte Inc. | Lion TCR Pte. Ltd. | Payment unspecified | 1/3/2024 |
| Roche to develop, manufacture and commercialize Medilink's YL-211 against solid tumors worldwide | Medilink Therapeutics (Suzhou) Co. Ltd. | Roche Holding AG | $1,050.00 | 1/2/2024 |
| Cytonus to develop and commercialize Medinno's Hiestem for ischemic encephalopathy in North American and MENA region | Medinno Inc. | Cytonus Therapeutics Inc. | Payment unspecified | 1/9/2024 |
| Repronovo to develop and commercialize Mereo Biopharma’s leflutrozole worldwide | Mereo Biopharma Group Ltd. | Repronovo SA | $64.25 | 1/8/2024 |
| Epivario acquires Metabomed's small molecule acetyl co-A synthetase-2 inhibitor against advanced cancer and CNS diseases | Metabomed Ltd. | Epivario Inc. | Payment unspecified | 1/16/2024 |
| Molecular Partners and Orano Med to develop 212Pb based Radio DARP in therapies against solid tumors | Molecular Partners AG | Orano Med SAS | Payment unspecified | 1/7/2024 |
| Roche to use Moma' Knowledgebase platform to discover, identify, develop and commercialize the drug targets against cancer | Moma Therapeutics Inc. | Roche Holding AG | $2,066.00 | 1/4/2024 |
| Sonoma Pharmaceuticals to commercialize Novabay Pharmaceuticals' Ocudox in the European Union | Novabay Pharmaceuticals Inc. | Sonoma Pharmaceuticals Inc. | Payment unspecified | 1/9/2024 |
| Chiesi Group and Oak Hill Bio to develop and commercialize OHB-607 to treat complications of extremely premature birth | Oak Hill Bio Corp. | Chiesi Farmaceutici SpA | Payment unspecified | 1/9/2024 |
| Astrazeneca to use Omniose's bioconjugation platform to develop vaccines against bacterial diseases | Omniose | Astrazeneca plc | Payment unspecified | 1/5/2024 |
| Lantheus to develop and commercialize Perspective's Pb212-VMT-?-NET against neuroendocrine tumors, with an option | Perspective Therapeutics Inc. | Lantheus Holdings Inc. | $28.00 | 1/9/2024 |
| Tenacia to develop and commercialize Praxis Precision's ulixacaltamide for treatment of essential tremor in China, Hong Kong, Macau, and Taiwan | Praxis Precision Medicines Inc. | Tenacia Biotechnology (Shanghai) Co. Ltd. | $279.00 | 1/5/2024 |
| TG Therapeutics to develop and commercialize Precision's azer-cel against autoimmune diseases worldwide | Precision Biosciences Inc. | TG Therapeutics Inc. | $305.50 | 1/9/2024 |
| Predicine and Janssen to develop Predicinecare urine cell-free DNA sequencing assay as a companion diagnostic against bladder cancer | Predicine Inc. | Janssen Pharmaceutica NV | Payment unspecified | 1/8/2024 |
| Recursion Pharmaceuticals licensed the rights to a new chemical entity from Bayer AG | Recursion Pharmaceuticals Inc. | Bayer AG | Payment unspecified | 1/4/2024 |
| Medison to commercialize Regeneron' Libtayo for BCC, CSCC, NSCLC and cervical cancer in Europe and other countries | Regeneron Pharmaceuticals Inc. | Medison Pharma Ltd. | Payment unspecified | 1/8/2024 |
| Remix Therapeutics and Roche to develop small-molecule therapeutics targeting the underlying drivers of disease | Remix Therapeutics Inc. | Roche Holding AG | $1,042.00 | 1/3/2024 |
| Ribocure and Boehringer to develop and commercialize siRNA therapeutics for nonalcoholic or metabolic dysfunction-associated steatohepatitis | Ribocure Pharmaceuticals AB | Boehringer Ingelheim International GmbH | $2,000.00 | 1/3/2024 |
| Flagship Pioneering and Samsung to support translational science and medicine development | Samsung C&T Corp. | Flagship Pioneering Inc. | Payment unspecified | 1/8/2024 |
| Sanofi exercised option for the second target to develop in vivo CRISPR-based therapeutics in an agreement with Scribe Therapeutics | Scribe Therapeutics Inc. | Sanofi SA | Payment unspecified | 1/2/2024 |
| Henlius Biotech to develop and commercialize Sermonix’s lasofoxifene for breast cancer in China | Sermonix Pharmaceuticals Inc. | Shanghai Henlius Biotech Inc. | $58.00 | 1/11/2024 |
| Novartis to develop and commercialize Argo Biopharma's phase I and phase I/IIa stage programs against cardiovascular disease worldwide | Shanghai Argo Biopharmaceutical Co. Ltd. | Novartis AG | $4,165.00 | 1/7/2024 |
| Janssen Biotech to develop and commercialize Simcha Therapeutics' DR-18 armored cell therapy for cancer treatment | Simcha Therapeutics Holding Co. Inc. | Janssen Biotech Inc. | Payment unspecified | 1/8/2024 |
| Dong-A ST to commercialize SK biopharmaceuticals' cenobamate for epilepsy in 30 countries excluding the U.S. | SK Biopharmaceuticals Co. Ltd. | Dong-A ST Co. Ltd. | Payment unspecified | 1/4/2024 |
| Basilea to acquire Spexis' all preclinical antibiotics program and IP targeting the Gram-negative bacteria including multidrug-resistant strains | Spexis AG | Basilea Pharmaceutica Ltd. | $2.26 | 1/15/2024 |
| Debiopharm International secured an option to enter an exclusive licensing deal with Sunrock Biopharma for antibody-drug conjugates targeting HER3 | Sunrock Biopharma SL | Debiopharm International SA | Payment unspecified | 1/8/2024 |
| Syneos Health to provide commercialization services for Crossject' Zepizure for epileptic seizures | Syneos Health UK Ltd. | Crossject SA | Payment unspecified | 1/4/2024 |
| SyntheticGestalt and Enamine to develop a suite of AI models to facilitate drug discovery | Syntheticgestalt | Enamine Ltd. | Payment unspecified | 1/11/2024 |
| Essential Pharma acquires Teva' Colobreathe for chronic lung infection in Europe | Teva Laboratories U.K. Ltd. | Essential Pharma Group | Payment unspecified | 1/8/2024 |
| Thermo Fisher Scientific to provide manufacturing services for Galapagos' CAR-T hemato-oncology program | Thermo Fisher Scientific Inc. | Galapagos NV | Payment unspecified | 1/4/2024 |
| Ji Xing to develop TMS-007 for the treatment of resistant and/or uncontrolled hypertension worldwide; TMS regains Japan rights | TMS Co. Ltd. | Ji Xing Pharmaceuticals Ltd. | $372.50 | 1/12/2024 |
| Johnson & Johnson exercised option to develop and commercialize therapeutics against selected targets in an agreement with Trex Bio | Trex Bio Inc. | Johnson & Johnson | Payment unspecified | 1/3/2024 |
| AstraZeneca to use Turbine' simulated cell platform to identify and understand mechanisms of resistance of therapy used in hematological cancers | Turbine Ltd. | Astrazeneca plc | Payment unspecified | 1/5/2024 |
| Abbvie and Umoja Biopharma to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Vivovec platform | Umoja Biopharma Inc. | Abbvie Inc. | $1,044.00 | 1/4/2024 |
| An undisclosed company to formulate and perform sequence selection to prepare Nanogenics' ECP-105 for preclinical evaluation in post-surgical treatment of glaucoma | Undisclosed | Nanogenics Ltd. | Payment unspecified | 1/16/2024 |
| Vector Pharma to distribute Ascendis' Skytrofa, Yorvipath for growth hormone deficiency and hypoparathyroidism in Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain | Vector Pharma FZCO | Ascendis Pharma A/S | Payment unspecified | 1/8/2024 |
| Menarini to develop and commercialize Venatorx' cefepime plus taniborbactam in 96 countries in Europe, Latin America, Middle East, Turkey, North Africa and Commonwealth of Independent States | Venatorx Pharmaceuticals Inc. | The Menarini Group | Payment unspecified | 1/9/2024 |
| Novartis AG signed option agreement to use Voyager Therapeutics’ adeno-associated virus (AAV) capsids to develop gene therapies for Huntington’s disease (HD) and spinal muscular atrophy | Voyager Therapeutics Inc. | Novartis AG | $1,300.00 | 1/2/2024 |
| Walgreens to distribute Verrica's Ycanth against molluscum contagiosum | Walgreen Co. | Verrica Pharmaceuticals Inc. | Payment unspecified | 1/3/2024 |
| Biontech to develop and commercialize monoclonal antibody using Wuxi Biologics antibody discovery technology | Wuxi Bio Inc. | Biontech SE | $20.00 | 1/10/2024 |
| Wuxi XDC to sign memorandum of understanding with Intocell to advance the discovery and development of antibody drug conjugates | Wuxi XDC Cayman Inc. | Intocell Inc. | Payment unspecified | 1/2/2024 |
| Xcell and Elevatebio to develop technology for cell and gene therapies | Xcell Biosciences Inc. | Elevatebio LLC | Payment unspecified | 1/11/2024 |
| Amgen to develop and commercialize teprotumumab using Xeris' Xeriject technology for thyroid eye disease worldwide | Xeris Biopharma Holdings Inc. | Amgen Inc. | $75.00 | 1/10/2024 |
| Kexing Biopharm to commercialize Xiling Lab Eribulin Mesylate Injection against breast cancer in various countries | Xiling Lab Co. Ltd. | Kexing Biopharm Co. Ltd. | Payment unspecified | 1/3/2024 |
| Immunome licensed Zentalis Pharmaceuticals' ZPC-21 and ADC platform technology | Zentalis Pharmaceuticals Inc. | Immunome Inc. | $310.00 | 1/8/2024 |